Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Nancy Fusco"'
Autor:
Steven E. Waggoner, Nancy Fusco, Deborah A. Smith, Vivian E. von Gruenigen, Susan Eaton, Anne M. Heugel, Robert Debernardo, Heidi Frasure
Publikováno v:
Anti-Cancer Drugs. 23:724-730
The aim of this study was to determine the dose of weekly oral topotecan that allows safe administration and to evaluate the pharmacokinetics of this dose in patients with recurrent gynecologic malignancies. The first cohort of patients received oral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fcca9b00602b72f4a7bc1ad8a044cac
https://doi.org/10.1097/cad.0b013e32835396d4
https://doi.org/10.1097/cad.0b013e32835396d4
Autor:
Nancy Fusco, Michael W. Sill, Paula M. Fracasso, Aaron H. Wolfson, Amina Ahmed, S. Diane Yamada, Ritu Salani, D. Scott McMeekin, Peter G. Rose
Publikováno v:
Gynecologic Oncology. 125:158-162
To determine the maximum tolerated dose (MTD) and acute dose-limiting toxicities (DLT) of intravenous topotecan administered with weekly cisplatin during pelvic radiation therapy in patients with locally advanced cervical cancer.Patients were treated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::828daf5ce2832e417713b86760d58c44
https://doi.org/10.1016/j.ygyno.2011.12.431
https://doi.org/10.1016/j.ygyno.2011.12.431
Autor:
Elisa Eldermire, Robert Debernardo, Heidi Frasure, Vivian E. von Gruenigen, Nancy Fusco, Susan Eaton, Steven E. Waggoner
Publikováno v:
Cancer. 116:4735-4743
BACKGROUND: The objective of this study was to compare the incidence of hand-foot syndrome (HFS) in patients who received pyridoxine versus placebo during pegylated liposomal doxorubicin (PLD) chemotherapy for recurrent ovarian, breast, or endometria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa481374654cdc7b58984066dad9816b
https://doi.org/10.1002/cncr.25262
https://doi.org/10.1002/cncr.25262
Publikováno v:
American Journal of Clinical Oncology. 31:476-480
The feasibility, safety, and preliminary efficacy of a second-line combination therapy for oral topotecan and pegylated liposomal doxorubicin in patients with platinum-resistant or refractory epithelial ovarian, peritoneal, or tubal carcinoma were in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a154f12f78b2fcff55fda3076b99827a
https://doi.org/10.1097/coc.0b013e31816a6221
https://doi.org/10.1097/coc.0b013e31816a6221
Publikováno v:
Gynecologic Oncology. 107:274-279
Purpose To determine the maximum tolerated dose (MTD) of gemcitabine followed by cisplatin that can be administered weekly during pelvic radiation therapy in patients with locally advanced cervical cancer. Methods A phase I and feasibility study with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad08b1d59efe754a4ad4152d66bc4234
https://doi.org/10.1016/j.ygyno.2007.06.012
https://doi.org/10.1016/j.ygyno.2007.06.012
Publikováno v:
Gynecologic Oncology. 102:236-239
Preclinical models suggest synergy when topoisomerase I and II inhibitors are given sequentially, but not simultaneously. A phase I study was conducted in previously treated ovarian or peritoneal carcinoma to determine the tolerability (maximum numbe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::780f23766e161ac144e7cd763774081d
https://doi.org/10.1016/j.ygyno.2005.12.003
https://doi.org/10.1016/j.ygyno.2005.12.003
Autor:
Peter G. Rose, Michael Rodriguez, William P. McGuire, Joan L. Walker, Nancy Fusco, Benjamin E. Greer
Publikováno v:
Gynecologic Oncology. 85:136-139
In an effort to explore second-line therapy in ovarian, peritoneal, and tubal carcinoma, a phase I trial combining prolonged oral etoposide and liposomal doxorubicin was conducted by the Gynecologic Oncology Group.Liposomal doxorubicin (20 mg/m(2)) w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e040760727d431aa9d916055f10371c6
https://doi.org/10.1006/gyno.2002.6584
https://doi.org/10.1006/gyno.2002.6584
Autor:
Anita Schwandt, Steven E. Waggoner, Afshin Dowlati, John Wright, Nancy Fusco, Pingfu Fu, Vivian E. von Gruenigen, Robert M. Wenham, Susan Eaton, Heidi Frasure
Publikováno v:
Investigational new drugs. 32(4)
Background/Purpose This study was designed to evaluate the response and toxicity of sorafenib alone or when combined with carboplatin and paclitaxel in patients with platinum-sensitive, recurrent ovarian cancer, fallopian tube cancer, or primary peri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c53340ca5ddd788f6762c9d0d18a0617
https://pubmed.ncbi.nlm.nih.gov/24619298
https://pubmed.ncbi.nlm.nih.gov/24619298
Publikováno v:
Gynecologic Oncology. 82:323-328
The aim of this study was to evaluate the relative activity and tolerance of liposomal doxorubicin in recurrent ovarian, peritoneal, and tubal carcinoma at an initial dose of 40 or 50 mg/m(2) every 4 weeks.A retrospective single-institution study was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c97773a046325b9e50563374c1998aac
https://doi.org/10.1006/gyno.2001.6272
https://doi.org/10.1006/gyno.2001.6272